NSE filing, NSE: MOTILALOFS. Summary written from the filing by ALFA Finder's alert engine.
Motilal Oswal Financial Services Ltd: key numbers
- Share price
- ₹1,088.40
- Market cap
- ₹65,628 Cr
- Revenue (annual)
- ₹9,374 Cr
- Net profit (annual)
- ₹1,869 Cr
- P/E (TTM)
- 24.3×Sector 19.5×
- Promoter holding
- 66.71%-0.49% QoQ
- FII holding
- 6.71%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Motilal Oswal Financial Services Ltd
All →Motilal Oswal Financial Services Debt & Borrowing: ₹1,300 Cr
Motilal Oswal Financial Services confirmed timely payment of Rs 1,300 Crore commercial paper maturity. The payment was due and made on November 03, 2026.
- Value
- ₹1,300 Cr
Motilal Oswal Financial Services Debt & Borrowing: ₹1.1 Cr
Motilal Oswal Financial Services paid Rs. 72.48 lakh and Rs. 37.17 lakh interest on Series V and VII secured NCDs on October 30, 2026. Payment was made on the actual date, with no reason for delay.
- Value
- ₹1.10 Cr
Motilal Oswal Financial Services Earnings Call Transcript: Key Takeaways
Motilal Oswal posted strong profit growth driven by asset and wealth management, which now contribute 58% of operating PAT.
Motilal Oswal Financial Services Other Announcement
Motilal Oswal Financial Services certifies utilisation of proceeds from listed Commercial Papers issued in the quarter ended September 30, 2026, and adherence to listing conditions. This is a periodic regulatory compliance certificate.
Motilal Oswal Financial Services Management Change
Motilal Oswal Financial Services appointed Janak Dalal as Senior Management Personnel, effective October 29, 2026. He brings about three decades of custody and investment banking experience.
Motilal Oswal Financial Services Employee Stock Options
Motilal Oswal Financial Services granted 2,20,000 stock options to eligible employees under its ESOP Scheme X. No exercise price or monetary value is disclosed.
Other regulatory approval announcements
All →Dr. Reddy's Laboratories Regulatory Approval
Dr. Reddy's Laboratories received marketing authorization from Brazil's ANVISA for its generic semaglutide injection. The approval targets Brazil's diabetes market, estimated at approximately USD 244.6 million.
Alembic Pharmaceuticals Regulatory Approval
Alembic Pharmaceuticals received USFDA final approval for its generic Olopatadine Hydrochloride Ophthalmic Solution 0.7% ANDA. The product's US market is estimated at $20 million, per IQVIA.
Emmbi Industries Regulatory Approval
SEBI exempted the Makrand and Rinku Appalwar business trusts from SAST takeover rules for an internal family share transfer. Control and promoter shareholding remain unchanged.
Bliss GVS Pharma Regulatory Approval
Bliss GVS Pharma's UK subsidiary Asterisk Lifesciences received MHRA marketing authorisation for Mesalazine 1g Suppositories. The approval lets the subsidiary market the product in the UK.
John Cockerill India Regulatory Approval
John Cockerill India received Reserve Bank of India approval for acquiring shares of John Cockerill Metals International SA. This allows the company to proceed with the share-swap acquisition.
Gland Pharma Regulatory Approval
Gland Pharma received USFDA approval for Methylprednisolone Acetate Injectable Suspension USP in multiple vial formats. The product is bioequivalent to Pfizer's Depo-Medrol in a ~$214M US market.